PIK3CD N334T mutation induces p-AKT, p-BCL2, and MCL1 and confers resistance to naratuximab emtansine in the SU-DHL-4 parental cells. (A) Immunoblotting for AKT/p-AKT, BCL2/p-BCL2, and MCL1 in SU-DHL-4 parental and resistant. Representative of 2 independent experiments. (B) Data on the bar plots represent the protein quantification (normalized to vinculin and DMSO). (C) Representative MTT results obtained in parental SU-DHL-4 cells that have undergone genome editing to induce PIK3CD N334T mutation (red) or, as controls, a silent mutation in the same locus (N334N; yellow) and in parental SU-DHL-4 cells undertreated (blue) or transfected with a EGFP only (gray). Bar plot corresponds to IC₅₀ values. ∗P < .05. eGFP, enhanced green fluorescent protein.